• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Mometasone-Teva spray nasal suspension 50μg/dose 10g (60 dose) — Made in Czech Republic — Free Delivery

    Mometasone-Teva spray nasal suspension 50μg/dose 10g (60 dose) — Made in Czech Republic — Free Delivery


    Brand: TEVA
    Product Code: Mometasone-Teva
    Availability: In Stock
    $21.88
    Add to Cart

    Pharmacological properties

    Pharmacodynamics. Mometasone furoate is a synthetic corticosteroids for topical use, which has a pronounced anti-inflammatory effect. the local anti-inflammatory effect of mometasone furoate is manifested in doses at which there are no systemic effects.
    Basically, the mechanism of anti-inflammatory and anti-allergic action of mometasone furoate is associated with its ability to suppress the release of mediators of allergic reactions. Mometasone furoate significantly reduces the synthesis / release of leukotrienes from leukocytes of patients with allergic diseases. Mometasone furoate has been shown to be 10 times more active in cell culture than other steroids, including beclomethasone dipropionate, betamethasone, hydrocortisone, and dexamethasone, in inhibiting the synthesis / release of IL-1, IL-5, IL-6 and TNF-α. It is also a potent inhibitor of the production of Th2 cytokines, IL-4 and IL-5 from human CD4 + T cells. Mometasone furoate is also 6 times more active than beclomethasone dipropionate and betamethasone in relation to inhibition of IL-5 production.
    Studies with provocative tests with the application of antigens to the nasal mucosa revealed a high anti-inflammatory activity of mometasone furoate both in the early and in the late stages of an allergic reaction. This was confirmed by a decrease (compared with placebo) in the level of histamine and eosinophil activity, as well as a decrease (compared to the baseline) in the number of eosinophils, neutrophils and adhesion proteins of epithelial cells.
    A pronounced clinical effect in the first 12 hours of mometasone furoate administration was achieved in 28% of patients with seasonal allergic rhinitis. On average (50%) relief occurred within 35.9 hours. In addition, mometasone furoate was significantly effective in reducing the severity of eye symptoms (redness, lacrimation, itching) in patients with seasonal allergic rhinitis.
    It has been reported that mometasone furoate has shown significant clinical efficacy in relieving nasal congestion, reducing polyp size, and restoring olfaction compared to placebo in patients with nasal polyps.
    It was reported that mometasone furoate was highly effective in reducing the severity of rhinosinusitis symptoms compared to placebo in children aged 12 years and older. During 15 days of treatment, the symptoms of rhinosinusitis were assessed on the MSS (Major Symptom Score) symptom severity scale: facial pain, sinus pressure, pressure pain, sinus pain, rhinorrhea, mucus draining down the back of the throat, and nasal congestion. The efficacy of amoxicillin 500 mg 3 times a day did not significantly differ from placebo in reducing the severity of rhinosinusitis symptoms on the MSS scale. During the follow-up period after completion of treatment, the number of relapses in the mometasone furoate group was low and comparable to the amoxicillin and placebo group. The duration of treatment for acute rhinosinusitis greater than 15 days has not been evaluated.
    Pharmacokinetics. The bioavailability of mometasone furoate when used in the form of a nasal spray is 1% in blood plasma (according to data obtained using a sensitive method, the lower limit of quantitative determination of which is 0.25 pg / ml). A suspension of mometasone furoate is very poorly absorbed in the gastrointestinal tract, and a small amount that can be swallowed and absorbed undergoes active primary metabolism even before excretion, mainly in the form of metabolites in the bile and to some extent in the urine.

    Indications

    Treatment of seasonal or perennial allergic rhinitis in adults and children over the age of 3 years. It is recommended to start prophylactic treatment of moderate to severe allergic rhinitis 4 weeks before the expected start of the pollination season. treating nasal polyps and related symptoms, including nasal congestion and loss of smell, in patients 18 years of age and older.

    Application

    Before using the first dose, shake the bottle well and press the spray pump 10 times (until a homogeneous spray is obtained). If the spray pump has not been used for 14 days or longer, it is necessary to re-prepare the spray pump by pressing it twice until a homogeneous spray is obtained. shake the bottle well before each use. after using the number of doses indicated on the label, or 2 months after the first use, the bottle should be discarded.
    After the preparation of the spray pump of the preparation Mometasone-Teva, with each injection, approximately 100 mg of a suspension of mometasone furoate containing the equivalent of mometasone furoate monohydrate - 50 μg of mometasone furoate in each nasal passage is obtained.
    Treatment of seasonal or year-round allergic rhinitis: for adults (including the elderly) and children over the age of 12, the recommended prophylactic and therapeutic dose of the preparation is 2 injections (50 μg each) into each nasal passage once a day (total daily dose - 200 mcg). After achieving a therapeutic effect for maintenance therapy, it is advisable to reduce the dose to 1 injection into each nasal passage once a day (total daily dose - 100 mcg).
    If a decrease in the severity of the symptoms of the disease cannot be achieved by using the preparation in the recommended therapeutic dose, the daily dose can be increased to the maximum: 4 injections into each nasal passage once a day (total daily dose - 400 mcg). After a decrease in the severity of symptoms of the disease, a dose reduction is recommended.
    The preparation showed a clinically significant onset of action within 12 hours after the first use in some patients with seasonal allergic rhinitis. However, the maximum benefit from the treatment cannot be obtained in the first 48 hours, therefore the patient must continue to use it regularly to achieve the full therapeutic effect.
    For children aged 3–11 years, the recommended therapeutic dose is 1 injection (50 mcg) into each nasal passage once a day (total daily dose - 100 mcg).
    Treatment with mometasone furoate nasal spray in patients with a history of moderate to severe seasonal allergic rhinitis symptoms may be started several days before the expected start of the flowering season.
    Nasal polyps: for adults (including elderly patients), the recommended dose is 2 injections (50 mcg) into each nasal passage once a day (total daily dose is 200 mcg). If a decrease in the severity of the symptoms of the disease cannot be achieved after using the preparation for 5-6 weeks, the dose can be increased to 2 injections into each nasal passage 2 times a day (total daily dose - 400 mcg). After achieving the clinical effect, it is recommended to reduce the dose to 2 injections into each nasal passage once a day (total daily dose - 200 mcg). If symptom relief cannot be achieved after 5–6 weeks of preparation use, alternative treatments should be considered.
    The study of the efficacy and safety of mometasone furoate nasal spray for the treatment of nasal polyposis lasted 4 months.
    Children
    Seasonal or perennial allergic rhinitis. The safety and efficacy of Mometasone-Teva in children under 3 years of age have not been studied.
    Nasal and polyps. The safety and efficacy of Mometasone-Teva in children have not been studied.

    Contraindications

    Hypersensitivity to the active substance or any inactive component of the preparation. The preparation should not be used in the presence of untreated localized infection involving the nasal mucosa. due to the fact that corticosteroids have the ability to suppress wound healing, patients who have recently undergone surgery on the nasal cavity or have been injured cannot use nasal corticosteroids until healing occurs.

    Side effects

    Nosebleeds generally stopped spontaneously, were minor and occurred somewhat more often than with placebo (5%), no more often than with other nasal corticosteroids, which were studied and used as active control (up to 15%), as reported in clinical studies of allergic rhinitis. the incidence of all other adverse reactions was comparable to the incidence of adverse reactions with placebo. in patients treated with nasal polyposis, the overall incidence of adverse reactions was similar to that observed in patients with allergic rhinitis.
    The systemic effects of nasal corticosteroids are more likely to occur when used in high doses and over a long period.
    The following are adverse reactions (≥1%) observed in clinical trials in patients with allergic rhinitis or nasal polyposis and during post-marketing use, regardless of the indication for use.
    Adverse reactions are classified according to organ systems and frequency of occurrence. The incidence of adverse reactions is defined as follows: very often (≥1 / 10); often (≥1 / 100, 1/10); infrequently (≥1 / 1000, 1/100). The incidence of adverse reactions in post-marketing studies was considered unknown (cannot be estimated from the available data).
    Infections and infestations: often - pharyngitis, upper respiratory tract infections 1.
    From the immune system: unknown - hypersensitivity, including anaphylactic reactions, angioedema, bronchospasm and shortness of breath.
    From the nervous system: often - headache.
    From the side of the organ of vision: unknown - glaucoma, increased intraocular pressure, cataract, blurred vision.
    On the part of the respiratory system, chest and mediastinal organs: very often - nosebleeds2; often - nosebleeds, burning sensation of the nasal mucosa, irritation of the nasal mucosa, ulceration of the nasal mucosa; unknown - perforation of the nasal septum.
    From the gastrointestinal tract: often - throat irritation2; unknown - disturbances in taste and smell.
    1 Has been reported when used twice a day for the treatment of nasal polyposis.
    2 Has been reported infrequently when used twice daily for the treatment of nasal polyposis.
    Children. In children, the frequency of reported adverse reactions in clinical trials, for example, nosebleeds (6%), headache (3%), irritation of the nasal mucosa (2%) and sneezing (2%), was comparable to that with placebo.

    Special instructions

    The use of the preparation in young children should be carried out with the help of adults.
    The preparation should not be used in the presence of untreated local infection with involvement of the nasal mucosa in the process.
    The preparation Mometasone-Teva should be used with caution or not at all in patients with active or latent tuberculosis infection of the respiratory tract, as well as in untreated fungal, bacterial, systemic viral infections.
    In patients using GCS, immunity can potentially be suppressed, and they should be warned of the increased risk of infection through contact with persons with certain infectious diseases (such as chickenpox, measles), as well as the need to consult a doctor if such contact takes place.
    After 12 months of treatment with mometasone furoatom, there were no signs of atrophy of the nasal mucosa; in addition, mometasone furoate contributed to the normalization of the histological picture of the nasal mucosa. As with any long-term treatment, patients who have been using the preparation  for several months or longer should be periodically examined to identify possible changes in the nasal mucosa. In the event of the development of a local fungal infection of the nose or pharynx, it may be necessary to discontinue preparation therapy or conduct appropriate treatment. Irritation of the nasal and pharyngeal mucosa, which persists for a long time, may also be an indication for discontinuation of treatment.
    The use of the preparation Mometasone-Teva is not recommended in the case of the development of perforation of the nasal septum.
    In clinical studies, the incidence of nosebleeds was higher compared with placebo. Epistaxis was generally mild and stopped spontaneously.
    Mometasone-Teva contains benzalkonium chloride as a preservative, which may cause nasal irritation.
    Systemic effects of nasal corticosteroids may occur, in particular when high doses are used, intended for long-term use. These manifestations occur much less frequently than with the use of oral corticosteroids, they can be different in different patients and when taking different corticosteroids. Potential systemic effects may include Cushing's syndrome, cushingoid traits, suppression of adrenal function, growth retardation in children and adolescents, cataracts, glaucoma, and, less commonly, a number of psychological or behavioral effects, in particular psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (in especially in children).
    After the use of intranasal corticosteroids, cases of increased intraocular pressure have been reported.
    Patients switching to nasal spray treatment after prolonged therapy with systemic corticosteroids should be carefully monitored. Discontinuation of systemic corticosteroids in these patients may cause adrenal insufficiency. If these patients show signs and symptoms of adrenal insufficiency or withdrawal syndrome (for example, joint and / or muscle pain, fatigue and depression), despite the disappearance of nasal symptoms, the use of systemic corticosteroids should be resumed along with other treatments and appropriate measures taken. With such a transition, pre-existing allergic conditions, such as allergic conjunctivitis and eczema, may also appear, the manifestation of which was previously suppressed by therapy with systemic GCS. With long-term treatment with Mometasone-Teva, there were no signs of suppression of the function of the hypothalamic-pituitary-adrenal system.
    The use of doses in excess of the recommended ones can provoke clinically significant adrenal suppression. If there is evidence of the use of doses exceeding the recommended ones during periods of stress or planned operations, the likelihood of using additional systemic GCS should be considered.
    The safety and efficacy of Mometasone-Teva when used to treat unilateral polyps, polyps associated with cystic fibrosis, or polyps that completely cover the nasal cavity have not been studied.
    For unilateral polyps that have an unusual or asymmetrical appearance, especially with ulcers and bleeding, further evaluation is necessary.
    It is recommended to regularly measure the height of children receiving long-term treatment with nasal corticosteroids. If growth is slowed down, therapy should be revised in order to reduce the dose of nasal corticosteroids, if possible, to the minimum dose at which effective control of symptoms is maintained. In addition, the patient should be referred to a pediatrician for consultation.
    Although the preparation controls nasal symptoms in most patients, the simultaneous use of appropriate concomitant therapy can lead to an additional reduction in the severity of other symptoms, in particular from the eye.
    Such patients need to be specially convinced of the advisability of continuing the spray treatment. A change in therapy may also reveal allergic diseases (such as allergic conjunctivitis, eczema, etc.), which developed earlier and were masked by systemic GCS therapy.
    It was reported that when using mometasone furoate in children at a daily dose of 100 μg for 1 year, growth retardation was not observed.
    Patients should be warned to seek immediate medical attention if signs or symptoms of severe bacterial infection develop, such as fever, severe one-sided facial pain or toothache, orbital or periorbital swelling / edema, or worsening after initial improvement.
    Long-term use of benzalkonium chloride can cause swelling of the nasal mucosa. In the event of such a reaction (constantly stuffy nose), if possible, preparations for nasal use without preservatives should be used; however, if such medicines are not available, a different dosage form should be chosen.
    Use during pregnancy and lactation. Special studies of the preparation with the participation of pregnant women have not been conducted.
    Like other corticosteroids for intranasal use, Mometasone-Teva is used in pregnant women and women who are breastfeeding only if the expected benefit from its use justifies the potential risk to the mother, fetus or infant. Infants whose mothers used GCS during pregnancy should be carefully examined for possible adrenal hypofunction.
    It is not known whether mometasone furoate is excreted in breast milk. As with the use of other nasal corticosteroids, it is necessary to stop breastfeeding or stop / abstain from mometasone furoate nasal spray therapy, taking into account the benefits of breastfeeding for the child and the benefits of therapy for the woman.
    There are no clinical data on the effect of mometasone furoate on fertility. Animal studies have shown reproductive toxicity, but there is no effect on fertility.
    The ability to influence the reaction rate when driving or working with other mechanisms. Unknown.

    Interactions

    The preparation was used concurrently with loratadine, with no effect on the plasma concentration of loratadine or its main metabolite, and mometasone furoate was not detected in the blood plasma even at the minimum concentration. the combination therapy was well tolerated by the patients.
    Data on interactions with other preparations are not presented.

    Overdose

    Due to the fact that the systemic bioavailability of the drpreparation g is insignificant (1%), it is unlikely that in case of an overdose, other measures will be required, besides monitoring the patient's condition, followed by the use of the preparation at the recommended dose.
    Inhalation or oral administration of excessive doses of GCS can lead to inhibition of the function of the hypothalamic-pituitary-adrenal system.

    Storage conditions

    At a temperature not exceeding 25 ° c. do not freeze.

    There are no reviews for this product.
    VEV Healthcare Store © 2017